

Title (en)
INTEGRIN ANTAGONISTS

Title (de)
INTEGRIN ANTAGONISTEN

Title (fr)
ANTAGONISTES DE L'INTEGRINE

Publication
EP 0946164 A4 20000823 (EN)

Application
EP 97913775 A 19971027

Priority
• GB 9626308 A 19961218
• US 9719349 W 19971027
• US 2922396 P 19961030

Abstract (en)
[origin: WO9818461A1] This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as vitronectin receptor antagonists. The vitronectin receptor antagonist compounds of the present invention are alpha v beta 3 antagonists, alpha v beta 5 antagonists or dual alpha v beta 3/ alpha v beta 5 antagonists useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation and tumor growth.

IPC 1-7
C07D 471/04; A61K 31/435; C07D 239/42; C07D 213/74; C07D 239/14; A61K 31/44; A61K 31/505

IPC 8 full level
A61K 31/18 (2006.01); **A61K 31/192** (2006.01); **A61K 31/195** (2006.01); **A61K 31/437** (2006.01); **A61K 31/4375** (2006.01); **A61K 31/44** (2006.01); **A61K 31/505** (2006.01); **A61P 9/00** (2006.01); **A61P 9/10** (2006.01); **A61P 19/10** (2006.01); **A61P 27/02** (2006.01); **A61P 29/00** (2006.01); **A61P 35/00** (2006.01); **A61P 43/00** (2006.01); **C07D 213/73** (2006.01); **C07D 213/74** (2006.01); **C07D 239/12** (2006.01); **C07D 239/14** (2006.01); **C07D 239/42** (2006.01); **C07D 471/04** (2006.01)

CPC (source: EP)
A61P 9/00 (2017.12); **A61P 9/10** (2017.12); **A61P 19/10** (2017.12); **A61P 27/02** (2017.12); **A61P 29/00** (2017.12); **A61P 35/00** (2017.12); **A61P 43/00** (2017.12); **C07D 213/73** (2013.01); **C07D 213/74** (2013.01); **C07D 239/12** (2013.01); **C07D 239/14** (2013.01); **C07D 239/42** (2013.01); **C07D 471/04** (2013.01)

Citation (search report)
• [E] WO 9844797 A1 19981015 - MERCK & CO INC [US], et al
• [E] WO 9825892 A1 19980618 - LILLY CO ELI [US], et al
• [PA] EGBERTSON M S ET AL: "Nonpeptide GPIIb/IIIa inhibitors. 10. centrally constrained alpha-sulfonamides are potent inhibitors of platelet aggregation", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,GB,OXFORD, vol. 6, no. 21, 5 November 1996 (1996-11-05), pages 2519 - 2524, XP004135906, ISSN: 0960-894X
• See references of WO 9818461A1

Designated contracting state (EPC)
AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

DOCDB simple family (publication)
WO 9818461 A1 19980507; AU 5088498 A 19980522; AU 717283 B2 20000323; EP 0946164 A1 19991006; EP 0946164 A4 20000823; JP 2001504456 A 20010403

DOCDB simple family (application)
US 9719349 W 19971027; AU 5088498 A 19971027; EP 97913775 A 19971027; JP 52063998 A 19971027